Literature DB >> 15013428

ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3.

Satsuki Mochizuki1, Masayuki Shimoda, Takayuki Shiomi, Yutaka Fujii, Yasunori Okada.   

Abstract

ADAM28, a member of a disintegrin and metalloproteinase (ADAM) family, has two isoforms, membrane-type form (ADAM28m) and secreted form (ADAM28s). Although ADAM28 is expressed and synthesized in a precursor form (proADAM28) by lymphocytes and some cancer cells, its activation mechanism and substrates remain unclear. Here, we report that proADAM28s of 65kDa is processed with active matrix metalloproteinase-7 (MMP-7) to 42- and 40-kDa forms which corresponds to active ADAM28s without propeptide. Processed ADAM28s digested insulin-like growth factor binding protein-3 (IGFBP-3) in both free and complex forms with IGF-I or IGF-II, and the digestion was prevented with EDTA, 1,10-phenanthroline, KB-R7785, tissue inhibitor of metalloproteinases-3 (TIMP-3), and TIMP-4. These data provide the first evidence that proADAM28s is activated by MMP-7 and ADAM28 digests IGFBP-3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013428     DOI: 10.1016/j.bbrc.2004.01.022

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

Review 2.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

3.  ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α.

Authors:  Jeremy B M Jowett; Yasunori Okada; Peter J Leedman; Joanne E Curran; Matthew P Johnson; Eric K Moses; Harald H H Goring; Satsuki Mochizuki; John Blangero; Leah Stone; Holly Allen; Chris Mitchell; Vance B Matthews
Journal:  Immunol Cell Biol       Date:  2012-09-25       Impact factor: 5.126

4.  Bone morphogenetic protein-1 processes insulin-like growth factor-binding protein 3.

Authors:  Byoungjae Kim; Guorui Huang; Wen-Bin Ho; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2011-06-22       Impact factor: 5.157

Review 5.  TIMPs: versatile extracellular regulators in cancer.

Authors:  Hartland W Jackson; Virginie Defamie; Paul Waterhouse; Rama Khokha
Journal:  Nat Rev Cancer       Date:  2016-12-09       Impact factor: 60.716

6.  Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.

Authors:  Yan-ling Lv; Dong-mei Yuan; Qing-bo Wang; Ping Zhan; Liang Luo; Tang-feng Lv; Hong-bing Liu; Yu-feng Li; Jian Wen; Yong Song
Journal:  Med Oncol       Date:  2012-02-22       Impact factor: 3.064

Review 7.  ADAM8: a new therapeutic target for asthma.

Authors:  Martin D Knolle; Caroline A Owen
Journal:  Expert Opin Ther Targets       Date:  2009-05       Impact factor: 6.902

Review 8.  Unraveling insulin-like growth factor binding protein-3 actions in human disease.

Authors:  Sherryline Jogie-Brahim; David Feldman; Youngman Oh
Journal:  Endocr Rev       Date:  2009-05-28       Impact factor: 19.871

9.  Genome-wide host responses against infectious laryngotracheitis virus vaccine infection in chicken embryo lung cells.

Authors:  Jeongyoon Lee; Walter G Bottje; Byung-Whi Kong
Journal:  BMC Genomics       Date:  2012-04-24       Impact factor: 3.969

10.  miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.

Authors:  Nadia Felli; Federica Felicetti; Anna Maria Lustri; M Cristina Errico; Lisabianca Bottero; Alessio Cannistraci; Alessandra De Feo; Marina Petrini; Francesca Pedini; Mauro Biffoni; Ester Alvino; Massimo Negrini; Manuela Ferracin; Gianfranco Mattia; Alessandra Carè
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.